| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CELA2B |
| Uniprot No | P08218 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-269aa |
| 氨基酸序列 | MLGGEEARPNSWPWQVSLQYSSNGQWYHTCGGSLIANSWVLTAAHCISSSGIYRVMLGQHNLYVAESGSLAVSVSKIVVHKDWNSDQVSKGNDIALLKLANPVSLTDKIQLACLPPAGTILPNNYPCYVTGWGRLQTNGALPDDLKQGQLLVVDYATCSSSGWWGSTVKTNMICAGGDGVICTCNGDSGGPLNCQASDGRWEVHGIGSLTSVLGCNYYYKPSIFTRVSNYNDWINSVIANN |
| 预测分子量 | 38.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CELA2B重组蛋白的参考文献示例(注：部分文献信息为模拟概括，建议通过学术数据库核实具体内容)：
1. **文献名称**: "Recombinant expression and functional characterization of human CELA2B in pancreatic enzyme activation"
**作者**: Tanaka, K., et al.
**摘要**: 本研究通过大肠杆菌表达系统成功制备了重组人CELA2B蛋白，并验证其作为胰蛋白酶家族成员的酶活性。实验表明，CELA2B在体外能有效水解特定底物，提示其在胰腺消化功能中的潜在作用。
2. **文献名称**: "Structural insights into CELA2B protease by X-ray crystallography and mutagenesis analysis"
**作者**: Müller, R., & Schmidt, A.
**摘要**: 通过X射线晶体学解析了重组CELA2B蛋白的三维结构，揭示了其催化三联体的构象特征。突变实验证实了关键氨基酸残基(如His57、Asp102)在底物结合和酶活性中的必要性。
3. **文献名称**: "CELA2B overexpression correlates with tumor progression in colorectal cancer"
**作者**: Chen, L., et al.
**摘要**: 研究利用重组CELA2B蛋白制备抗体，分析其在结直肠癌组织中的表达水平。结果显示，CELA2B的高表达与肿瘤侵袭性和患者预后不良显著相关，提示其可能作为癌症生物标志物。
4. **文献名称**: "Optimization of CELA2B recombinant protein production in Pichia pastoris for biomedical applications"
**作者**: Gupta, S., & Lee, J.
**摘要**: 通过毕赤酵母表达系统优化CELA2B重组蛋白的分泌表达条件，获得高纯度活性蛋白。该研究为大规模生产CELA2B用于药物筛选或疾病模型研究提供了技术方案。
---
**注意事项**：
- 以上文献为示例性概括，实际研究请通过PubMed/Google Scholar检索关键词(如"CELA2B recombinant"、"Chymotrypsin-like elastase 2B")。
- 推荐补充真实文献数据库中的DOI或PMID编号以确保引用准确性。
**Background of CELA2B Recombinant Protein**
Chymotrypsin-like elastase family member 2B (CELA2B) is a serine protease belonging to the chymotrypsin family, primarily expressed in the pancreas as a zymogen (proenzyme). It plays a role in digestive processes by cleaving peptide bonds, particularly those adjacent to hydrophobic amino acids. CELA2B is synthesized as an inactive precursor, which undergoes proteolytic activation in the duodenum to participate in protein digestion. Beyond its physiological role, dysregulation of CELA2B has been linked to pancreatic disorders, including pancreatitis and pancreatic cancer, where aberrant protease activity may contribute to tissue damage or tumor progression.
Recombinant CELA2B protein is engineered using biotechnological methods, often expressed in heterologous systems like *E. coli*, yeast, or mammalian cells. This approach allows large-scale production of the purified enzyme for research and therapeutic applications. The recombinant form typically retains the enzymatic activity and structural features of the native protein, enabling studies on substrate specificity, inhibitor screening, and molecular mechanisms underlying pancreatic diseases.
In biomedical research, CELA2B recombinant protein is utilized to model digestive processes, investigate protease-inhibitor interactions, and explore its potential as a biomarker or therapeutic target. Its role in extracellular matrix remodeling and immune modulation has also sparked interest in inflammatory and oncological studies. Additionally, recombinant CELA2B serves as a critical tool for developing enzyme replacement therapies or targeted drugs, particularly for conditions involving protease dysregulation.
Overall, CELA2B recombinant protein bridges basic science and clinical applications, offering insights into pancreatic biology and disease pathways while supporting innovation in diagnostics and treatment strategies.
×
